Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free CTOR Stock Alerts

Citius Oncology (CTOR) Financials

Citius Oncology logo
$0.68 0.00 (-0.44%)
As of 03:48 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Citius Oncology

Annual Income Statements for Citius Oncology

This table shows Citius Oncology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 9/30/2023 9/30/2024 9/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 0.38 -13 -21 -25
Consolidated Net Income / (Loss)		 0.38 -13 -21 -25
Net Income / (Loss) Continuing Operations		 0.38 -13 -21 -25
Total Pre-Tax Income 		0.38 -12 -21 -24
Total Operating Income		 -0.14 -12 -21 -24
Total Gross Profit		 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00
Operating Revenue		 - 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00
Total Operating Expenses		 0.14 12 21 24
Selling, General & Admin Expense		 0.14 5.92 8.15 8.78
Research & Development Expense		 - 4.24 4.93 6.42
Other Special Charges / (Income)		 - 1.97 7.50 8.32
Total Other Income / (Expense), net		 0.52 0.00 0.00 -0.18
Interest Expense		 - - - 0.22
Interest & Investment Income		 0.49 - 0.00 0.04
Income Tax Expense		 - 0.58 0.58 1.06
Basic Earnings per Share		 $0.12 ($0.19) ($0.31) ($0.34)
Weighted Average Basic Shares Outstanding		 1.34M 67.50M 68.05M 73.27M
Diluted Earnings per Share		 $0.12 ($0.19) ($0.31) ($0.34)
Weighted Average Diluted Shares Outstanding		 1.34M 67.50M 68.05M 73.27M

Quarterly Income Statements for Citius Oncology

This table shows Citius Oncology's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -14 -4.73 -4.84 -4.77 -6.81 -6.66 -7.74 -5.37 -5.00 -5.53 -27
Consolidated Net Income / (Loss)		 -14 -4.73 -4.84 -4.77 -6.81 -6.66 -7.74 -5.37 -5.00 -5.53 -27
Net Income / (Loss) Continuing Operations		 -14 -4.73 -4.84 -4.77 -6.81 -6.66 -7.74 -5.37 -5.00 -5.53 -27
Total Pre-Tax Income 		-14 -4.58 -4.69 -4.63 -6.67 -6.39 -7.47 -5.11 -4.73 -5.27 -27
Total Operating Income		 -11 -4.58 -4.69 -4.63 -6.67 -6.39 -7.47 -4.94 -4.71 -5.25 -29
Total Gross Profit		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 3.15 1.34
Total Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 3.94 1.67
Operating Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 3.94 1.67
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.79 0.33
Operating Cost of Revenue		 - - - - - 0.00 0.00 - - 0.79 0.33
Total Operating Expenses		 11 4.58 4.69 4.63 6.67 6.39 7.47 4.94 4.71 8.41 30
Selling, General & Admin Expense		 5.15 1.52 1.39 1.54 3.71 3.32 2.24 1.88 1.34 2.86 24
Research & Development Expense		 - 1.15 1.35 1.13 1.30 1.26 3.14 0.94 1.08 1.59 2.80
Other Special Charges / (Income)		 - 1.92 - 1.96 - 1.81 2.09 2.13 - 3.96 3.53
Total Other Income / (Expense), net		 -2.15 0.00 0.00 0.00 - 0.00 0.00 -0.16 -0.02 -0.02 1.77
Interest Expense		 - - - 0.00 - 0.00 0.00 0.16 - 0.05 0.03
Interest & Investment Income		 - - - - - 0.00 0.00 - - 0.03 0.04
Other Income / (Expense), net		 - - - - - 0.00 0.00 - - - 1.76
Income Tax Expense		 - 0.14 0.14 0.14 0.14 0.26 0.26 0.26 0.26 0.26 -0.23
Basic Earnings per Share		 ($0.35) ($0.07) ($0.07) ($0.07) ($0.10) ($0.09) ($0.11) ($0.08) ($0.06) ($0.06) ($0.27)
Weighted Average Basic Shares Outstanding		 67.50M 67.50M 67.50M 67.50M 68.05M 71.55M 71.55M 71.55M 73.27M 87.46M 100.03M
Diluted Earnings per Share		 ($0.35) ($0.07) ($0.07) ($0.07) ($0.10) ($0.09) ($0.11) ($0.08) ($0.06) ($0.06) ($0.27)
Weighted Average Diluted Shares Outstanding		 67.50M 67.50M 67.50M 67.50M 68.05M 71.55M 71.55M 71.55M 73.27M 87.46M 100.03M

Annual Cash Flow Statements for Citius Oncology

This table details how cash moves in and out of Citius Oncology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 9/30/2023 9/30/2024 9/30/2025
Net Change in Cash & Equivalents		 0.29 0.00 0.00 3.92
Net Cash From Operating Activities		 -0.05 0.00 0.13 -5.49
Net Cash From Continuing Operating Activities		 -0.05 0.00 0.13 -5.49
Net Income / (Loss) Continuing Operations		 0.38 -13 -21 -25
Consolidated Net Income / (Loss)		 0.38 -13 -21 -25
Non-Cash Adjustments To Reconcile Net Income		 -0.49 17 22 17
Changes in Operating Assets and Liabilities, net		 0.06 -4.07 -0.49 2.02
Net Cash From Investing Activities		 -67 0.00 -5.00 -5.75
Net Cash From Continuing Investing Activities		 -67 0.00 -5.00 -5.75
Acquisitions		 - 0.00 -5.00 -5.75
Net Cash From Financing Activities		 68 0.00 4.87 15
Net Cash From Continuing Financing Activities		 68 0.00 4.87 15
Payment of Dividends		 - 0.00 -2.75 0.00
Issuance of Debt		 0.00 0.00 3.80 0.00
Issuance of Common Equity		 69 - 0.00 15
Other Financing Activities, net		 -1.57 0.00 3.83 0.00
Cash Interest Paid		 - - 0.00 0.19

Quarterly Cash Flow Statements for Citius Oncology

This table details how cash moves in and out of Citius Oncology's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 0.26 0.00 - - 0.00 0.00 - - 3.92 3.37 -4.66
Net Cash From Operating Activities		 0.38 0.00 - - 0.13 0.00 - - -5.49 -7.35 -3.83
Net Cash From Continuing Operating Activities		 0.38 0.00 - - 0.13 0.00 - - -5.49 -7.35 -3.83
Net Income / (Loss) Continuing Operations		 -14 -4.73 -4.84 -4.77 -6.81 -6.66 -7.74 -5.37 -5.00 -5.53 -27
Consolidated Net Income / (Loss)		 -14 -4.73 -4.84 -4.77 -6.81 -6.66 -7.74 -5.37 -5.00 -5.53 -27
Amortization Expense		 - - - - - 0.00 - - - 0.57 1.72
Non-Cash Adjustments To Reconcile Net Income		 19 5.87 5.62 5.79 4.49 4.12 4.13 4.65 4.35 5.94 0.25
Changes in Operating Assets and Liabilities, net		 -4.46 -1.14 -0.79 -1.01 2.45 2.54 3.60 0.72 -4.84 -8.33 21
Net Cash From Investing Activities		 0.66 0.00 - - -5.00 0.00 - - -5.75 -4.40 -0.60
Net Cash From Continuing Investing Activities		 0.66 0.00 - - -5.00 0.00 - - -5.75 -4.40 -0.60
Acquisitions		 - - - - - 0.00 - - - -4.40 -0.60
Net Cash From Financing Activities		 -0.78 0.00 - - 4.87 0.00 - - 15 15 -0.23
Net Cash From Continuing Financing Activities		 -0.78 0.00 - - 4.87 0.00 - - 15 15 -0.23
Issuance of Common Equity		 - - - - - 0.00 - - - 15 -0.06

Annual Balance Sheets for Citius Oncology

This table presents Citius Oncology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 9/30/2024 9/30/2025
Total Assets		 0.13 68 73 84 101
Total Current Assets		 0.00 0.38 0.06 11 28
Cash & Equivalents		 - 0.29 0.03 0.00 3.92
Accounts Receivable		 - - - - 0.00
Inventories, net		 - - - 8.27 22
Prepaid Expenses		 - 0.09 0.03 2.70 1.33
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.13 68 73 73 73
Intangible Assets		 - - - - 73
Other Noncurrent Operating Assets		 0.13 - - 73 0.00
Total Liabilities & Shareholders' Equity		 0.13 68 73 84 101
Total Liabilities		 0.14 0.03 2.05 38 56
Total Current Liabilities		 0.14 0.03 2.05 33 49
Accounts Payable		 0.13 - - 3.71 13
Accrued Expenses		 0.01 0.03 0.38 0.00 4.09
Other Current Liabilities		 - 0.00 0.34 29 32
Total Noncurrent Liabilities		 0.00 0.00 0.00 1.73 6.59
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - 1.73 2.78
Other Noncurrent Operating Liabilities		 - 0.00 - - 3.80
Total Equity & Noncontrolling Interests		 -0.01 0.35 -1.99 46 45
Total Preferred & Common Equity		 -0.01 0.35 -1.99 46 45
Preferred Stock		 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -0.01 0.35 -1.99 46 45
Common Stock		 0.03 0.00 0.00 85 109
Retained Earnings		 -0.01 0.35 -1.99 -39 -64

Quarterly Balance Sheets for Citius Oncology

This table presents Citius Oncology's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 12/31/2024 3/31/2025 6/30/2025 12/31/2025 3/31/2026
Total Assets		 71 49 49 90 91 92 110 101
Total Current Assets		 0.09 0.09 0.04 17 18 18 37 29
Cash & Equivalents		 0.03 0.03 0.00 0.00 0.00 0.00 7.30 2.63
Accounts Receivable		 - - - - - - 4.05 1.08
Inventories, net		 - - - 14 15 17 23 23
Prepaid Expenses		 0.06 0.06 0.04 2.70 2.70 1.10 3.16 3.05
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 71 49 49 73 73 73 73 71
Intangible Assets		 - - - - - - - 71
Other Noncurrent Operating Assets		 - 0.00 - 73 73 73 73 0.17
Total Liabilities & Shareholders' Equity		 71 49 49 90 91 92 110 101
Total Liabilities		 1.17 2.82 3.08 49 56 59 52 65
Total Current Liabilities		 1.17 2.82 3.08 43 50 53 45 59
Accounts Payable		 - - - 5.87 7.68 8.67 10 8.88
Accrued Expenses		 0.39 0.49 0.49 6.23 8.72 8.46 4.52 24
Other Current Liabilities		 0.78 0.81 0.87 2.90 4.94 7.46 11 26
Total Noncurrent Liabilities		 0.00 0.00 0.00 30 31 31 21 6.62
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - 1.99 2.26 2.52 3.05 2.82
Other Noncurrent Operating Liabilities		 - - - 28 28 28 18 3.80
Total Equity & Noncontrolling Interests		 -1.08 -2.46 -3.04 41 36 32 58 35
Total Preferred & Common Equity		 -1.08 -2.46 -3.04 41 36 32 58 35
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -1.08 -2.46 -3.04 41 36 32 58 35
Common Stock		 0.00 0.00 0.00 87 89 91 128 131
Retained Earnings		 -1.08 -2.46 -3.04 -46 -54 -59 -70 -96

Annual Metrics And Ratios for Citius Oncology

This table displays calculated financial ratios and metrics derived from Citius Oncology's official financial filings.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 9/30/2023 9/30/2024 9/30/2025
DEI Shares Outstanding		 8,941,000.00 8,941,000.00 2,355,249.00 2,355,249.00
DEI Adjusted Shares Outstanding		 8,941,000.00 8,941,000.00 2,355,249.00 2,355,249.00
DEI Earnings Per Adjusted Shares Outstanding		 0.04 -1.42 -8.98 -10.51
Growth Metrics		 - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -10,702.38% -69.72% -14.34%
EBIT Growth		 0.00% -10,702.38% -69.72% -14.34%
NOPAT Growth		 0.00% -6,043.34% -69.72% -14.34%
Net Income Growth		 0.00% -3,434.26% -66.56% -17.08%
EPS Growth		 0.00% -258.33% -63.16% -9.68%
Operating Cash Flow Growth		 0.00% 100.00% 0.00% -4,446.59%
Free Cash Flow Firm Growth		 0.00% 0.00% -741.61% 82.68%
Invested Capital Growth		 0.00% -1,343.16% 7,231.20% -10.41%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% -1,236.34% 18.54% 7.68%
EBIT Q/Q Growth		 0.00% -1,236.34% 18.54% 7.68%
NOPAT Q/Q Growth		 0.00% -835.44% 18.54% 7.68%
Net Income Q/Q Growth		 0.00% -818.67% 25.58% 6.83%
EPS Q/Q Growth		 0.00% -167.86% 44.64% 10.53%
Operating Cash Flow Q/Q Growth		 0.00% 100.00% -66.97% -4,446.59%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -246.16% 79.15%
Invested Capital Q/Q Growth		 0.00% 36.91% 0.00% 23.60%
Profitability Metrics		 - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 104.75% 102.80% 104.46%
Interest Burden Percent		 -339.38% 100.00% 100.00% 100.77%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 1.12% -18.30% -36.24% -54.42%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -130.24% -23.80%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.01% 0.22% -13.71% -54.42%
Return on Equity Simple (ROE_SIMPLE)		 110.22% 638.84% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.14 -8.48 -14 -16
NOPAT Margin		 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.76% -6.04% -20.00% 451.43%
Return On Investment Capital (ROIC_SIMPLE)		 - 1,271.02% -28.84% -33.83%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -0.11 -12 -21 -24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.11 -12 -21 -24
Valuation Ratios		 - - - -
Price to Book Value (P/BV)		 39.46 0.00 2.05 3.32
Price to Tangible Book Value (P/TBV)		 39.46 0.00 2.05 3.32
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 35.80 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 2.79% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 236.86 0.00 1.97 3.32
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 778.73 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - -
Debt to Equity		 0.00 0.02 0.08 0.08
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00
Financial Leverage		 -1.00 -1.00 -0.58 0.04
Leverage Ratio		 1.00 1.02 1.35 2.04
Compound Leverage Factor		 -3.40 1.02 1.35 2.05
Debt to Total Capital		 0.00% 1.84% 7.61% 7.81%
Short-Term Debt to Total Capital		 0.00% 1.84% 7.61% 7.81%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 99.49% 100.93% 0.00% 0.00%
Common Equity to Total Capital		 0.51% -2.76% 92.39% 92.19%
Debt to EBITDA		 0.00 -0.11 -0.18 -0.16
Net Debt to EBITDA		 0.00 5.88 -0.18 0.01
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.16 -0.26 -0.23
Net Debt to NOPAT		 0.00 8.40 -0.26 0.01
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00
Altman Z-Score		 256.93 212.59 -0.28 -0.33
Noncontrolling Interest Sharing Ratio		 99.51% 101.18% 62.17% 0.00%
Liquidity Ratios		 - - - -
Current Ratio		 11.85 0.03 0.34 0.56
Quick Ratio		 9.08 0.02 0.00 0.08
Cash Flow Metrics		 - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -7.73 -65 -11
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -51.68
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 -25.19
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 -25.19
Efficiency Ratios		 - - - -
Asset Turnover		 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - -
Invested Capital		 0.06 -0.70 50 45
Invested Capital Turnover		 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -0.76 51 -5.20
Enterprise Value (EV)		 13 728 98 149
Market Capitalization		 14 727 95 149
Book Value per Share		 $0.04 ($0.22) $19.59 $0.61
Tangible Book Value per Share		 $0.04 ($0.22) $19.59 $0.61
Total Capital		 68 72 50 49
Total Debt		 0.00 1.32 3.80 3.80
Total Long-Term Debt		 0.00 0.00 0.00 0.00
Net Debt		 -68 -71 3.80 -0.12
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.06 -0.70 -18 -22
Debt-free Net Working Capital (DFNWC)		 0.35 -0.67 -18 -18
Net Working Capital (NWC)		 0.35 -1.99 -22 -22
Net Nonoperating Expense (NNE)		 -0.52 4.21 6.75 8.30
Net Nonoperating Obligations (NNO)		 -68 -71 3.80 -0.12
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - -
Adjusted Basic Earnings per Share		 $0.12 $0.27 ($0.31) ($0.34)
Adjusted Weighted Average Basic Shares Outstanding		 1.87M 6.60M 68.05M 73.27M
Adjusted Diluted Earnings per Share		 $0.12 $0.27 ($0.31) ($0.34)
Adjusted Weighted Average Diluted Shares Outstanding		 1.34M 6.60M 68.05M 73.27M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 4.70M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -0.10 -7.11 -9.15 -11
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 -107.89
NOPAT to Interest Expense		 0.00 0.00 0.00 -75.52
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 -107.89
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 -75.52
Payout Ratios		 - - - -
Dividend Payout Ratio		 0.00% 0.00% -13.02% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -13.02% 0.00%

Quarterly Metrics And Ratios for Citius Oncology

This table displays calculated financial ratios and metrics derived from Citius Oncology's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 8,941,000.00 8,941,000.00 8,941,000.00 6,653,077.00 2,355,249.00 2,355,249.00 2,355,249.00 2,355,249.00 2,355,249.00 2,355,249.00 2,355,249.00
DEI Adjusted Shares Outstanding		 8,941,000.00 8,941,000.00 8,941,000.00 6,653,077.00 2,355,249.00 2,355,249.00 2,355,249.00 2,355,249.00 2,355,249.00 2,355,249.00 2,355,249.00
DEI Earnings Per Adjusted Shares Outstanding		 -1.58 -0.53 -0.54 -0.72 -2.89 -2.83 -3.28 -2.28 -2.12 -2.35 -11.30
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -10,017.11% -849.26% -2,251.02% -998.30% 41.25% -39.52% -59.25% -6.83% 29.35% 26.84% -236.37%
EBIT Growth		 -10,017.11% -849.26% -2,251.02% -998.30% 41.25% -39.52% -59.25% -6.83% 29.35% 17.87% -259.40%
NOPAT Growth		 -5,653.62% -2,068.97% -1,545.71% -668.81% 41.25% -39.52% -59.25% -6.83% 29.35% 17.87% -282.98%
Net Income Growth		 -3,798.21% -872.80% -884.61% -3,121.88% 51.62% -40.86% -59.97% -12.51% 26.66% 16.90% -243.99%
EPS Growth		 -391.67% -200.00% -200.00% -450.00% 71.43% -28.57% -57.14% -14.29% 40.00% 33.33% -145.45%
Operating Cash Flow Growth		 897.46% 100.00% 0.00% 0.00% -66.97% 0.00% 0.00% 0.00% -4,446.59% 0.00% 0.00%
Free Cash Flow Firm Growth		 0.00% -1,915.33% -1,454.09% -741.26% -669.25% -2,417.30% -1,868.92% -811.68% 103.44% 73.42% 71.25%
Invested Capital Growth		 -1,343.16% -2,490.97% -254.84% 0.00% 7,231.20% 3,742.23% 3,087.60% 0.00% -10.41% 21.80% -17.26%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -57.73%
EBITDA Q/Q Growth		 -2,593.60% 59.63% -2.36% 1.34% -44.07% 4.11% -16.83% 33.81% 4.72% 0.69% -437.13%
EBIT Q/Q Growth		 -2,593.60% 59.63% -2.36% 1.34% -44.07% 4.11% -16.83% 33.81% 4.72% -11.48% -411.24%
NOPAT Q/Q Growth		 -1,785.52% 59.63% -2.36% 1.34% -44.07% 4.11% -16.83% 33.81% 4.72% -11.48% -444.78%
Net Income Q/Q Growth		 -9,016.64% 66.43% -2.29% 1.30% -42.74% 2.26% -16.16% 30.58% 6.95% -10.76% -380.83%
EPS Q/Q Growth		 -1,850.00% 80.00% 0.00% 0.00% -42.86% 10.00% -22.22% 27.27% 25.00% 0.00% -350.00%
Operating Cash Flow Q/Q Growth		 437.11% -100.00% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 0.00% -33.92% 47.90%
Free Cash Flow Firm Q/Q Growth		 -1,159.88% 71.93% -15.74% -86.23% -1,171.43% 8.14% 9.47% 13.77% 104.79% -810.49% 2.09%
Invested Capital Q/Q Growth		 36.91% -76.77% -6.64% 100.00% 0.00% -9.71% -12.52% -8.23% 23.60% 22.75% -40.57%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 79.99% 80.27%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -118.63% -1,507.31%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -133.17% -1,716.17%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -133.17% -1,610.49%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -140.31% -1,595.98%
Tax Burden Percent		 104.26% 103.14% 103.07% 103.11% 102.16% 104.13% 103.54% 105.18% 105.58% 105.01% 99.14%
Interest Burden Percent		 118.98% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 103.25% 100.44% 100.33% 99.96%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -7.35% -187.05%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,226.73% -1,314.40%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3.75% -21.64%
Return on Equity (ROE)		 -18.30% -78.32% -40.67% 0.00% -36.24% -52.97% -63.56% -82.04% -54.42% -11.10% -208.69%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% -130.24% -137.50% -148.01% -298.55% -23.80% -50.99% -65.65%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -5.24% -94.07%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -5.52% -93.22%
Return on Common Equity (ROCE)		 0.22% 3.84% 1.07% 0.00% -13.71% -23.60% -25.35% -82.04% -54.42% -11.10% -208.69%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 734.38% 772.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -7.95 -3.21 -3.28 -3.24 -4.67 -4.48 -5.23 -3.46 -3.30 -3.68 -20
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -93.22% -1,201.32%
Net Nonoperating Expense Percent (NNEP)		 -8.81% -6.42% -2.65% 0.00% -6.36% -10.08% -11.49% 100.45% 92.44% 1,219.38% 1,127.36%
Return On Investment Capital (ROIC_SIMPLE)		 1,190.39% 342.78% 248.80% - -9.35% -9.93% -13.26% -9.56% -6.78% -5.91% -56.79%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 20.01% 19.73%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 72.50% 1,417.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 40.36% 167.92%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 213.16% 1,796.44%
Earnings before Interest and Taxes (EBIT)		 -11 -4.58 -4.69 -4.63 -6.67 -6.39 -7.47 -4.94 -4.71 -5.25 -27
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -11 -4.58 -4.69 -4.63 -6.67 -6.39 -7.47 -4.94 -4.71 -4.68 -25
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 2.05 1.99 1.87 9.61 3.32 1.50 1.76
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 2.05 1.99 1.87 9.61 3.32 1.50 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 22.18 11.05
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 1.97 1.91 1.78 8.70 3.32 1.53 1.82
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 21.29 10.58
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 4,381.95 2,781.10 0.00 778.73 681.31 556.72 2,493.43 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.02 0.03 0.04 0.00 0.08 0.09 0.11 0.12 0.08 0.07 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.00 -1.03 -1.01 0.00 -0.58 -0.50 -0.53 0.12 0.04 0.00 0.02
Leverage Ratio		 1.02 2.55 1.03 0.00 1.35 1.60 1.72 2.83 2.04 2.01 2.71
Compound Leverage Factor		 1.21 2.55 1.03 0.00 1.35 1.60 1.72 2.92 2.05 2.02 2.71
Debt to Total Capital		 1.84% 3.21% 3.60% 0.00% 7.61% 8.43% 9.63% 10.50% 7.81% 6.11% 0.00%
Short-Term Debt to Total Capital		 1.84% 3.21% 3.60% 0.00% 7.61% 8.43% 9.63% 10.50% 7.81% 6.11% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 100.93% 101.98% 102.76% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -2.76% -5.18% -6.36% 0.00% 92.39% 91.57% 90.37% 89.50% 92.19% 93.89% 100.00%
Debt to EBITDA		 -0.11 -0.09 -0.08 0.00 -0.18 -0.17 -0.15 -0.15 -0.16 -0.17 0.00
Net Debt to EBITDA		 5.88 2.84 2.25 0.00 -0.18 -0.17 -0.15 -0.15 0.01 0.16 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.16 -0.13 -0.12 0.00 -0.26 -0.24 -0.22 -0.21 -0.23 -0.24 0.00
Net Debt to NOPAT		 8.40 4.06 3.22 0.00 -0.26 -0.24 -0.22 -0.21 0.01 0.22 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 212.63 156.72 144.91 0.00 0.26 -0.29 -0.79 1.62 0.29 -0.07 -1.94
Noncontrolling Interest Sharing Ratio		 101.18% 104.90% 102.63% 0.00% 62.17% 55.44% 60.12% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.03 0.03 0.01 0.00 0.34 0.39 0.36 0.35 0.56 0.83 0.50
Quick Ratio		 0.02 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.08 0.25 0.06
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -7.19 -2.02 -2.34 -4.35 -55 -51 -46 -40 1.90 -14 -13
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -246.71 0.00 -294.61 -400.32
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -160.44 -116.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -160.44 -116.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.04 0.06
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.04 0.06
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.10 0.14
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 8,560.84 6,202.38
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3,774.25 2,702.94
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4,786.58 3,499.44
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.70 -1.24 -1.32 0.00 50 45 39 36 45 55 33
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.08 0.16
Increase / (Decrease) in Invested Capital		 -0.76 -1.19 -0.95 1.11 51 46 41 36 -5.20 9.83 -6.81
Enterprise Value (EV)		 728 740 748 0.00 98 86 70 315 149 84 59
Market Capitalization		 727 738 747 767 95 82 67 311 149 87 62
Book Value per Share		 ($0.22) ($0.27) ($0.34) $0.00 $19.59 $0.58 $0.50 $0.45 $0.61 $0.67 $0.35
Tangible Book Value per Share		 ($0.22) ($0.27) ($0.34) $0.00 $19.59 $0.58 $0.50 $0.45 $0.61 $0.67 ($0.36)
Total Capital		 72 47 48 0.00 50 45 39 36 49 62 35
Total Debt		 1.32 1.52 1.72 0.00 3.80 3.80 3.80 3.80 3.80 3.80 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -71 -47 -47 0.00 3.80 3.80 3.80 3.80 -0.12 -3.50 -2.63
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.70 -1.24 -1.32 0.00 -18 -23 -28 -31 -22 -11 -32
Debt-free Net Working Capital (DFNWC)		 -0.67 -1.20 -1.32 0.00 -18 -23 -28 -31 -18 -3.76 -29
Net Working Capital (NWC)		 -1.99 -2.72 -3.04 0.00 -22 -26 -32 -35 -22 -7.56 -29
Net Nonoperating Expense (NNE)		 6.14 1.52 1.55 1.53 2.14 2.18 2.51 1.91 1.70 1.86 6.58
Net Nonoperating Obligations (NNO)		 -71 -47 -47 0.00 3.80 3.80 3.80 3.80 -0.12 -3.50 -2.63
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.57 1.72
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -280.39% -570.65%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -95.42% -523.73%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -191.77% -523.73%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.35) $0.07 $0.04 $0.00 ($0.10) ($0.09) ($0.11) ($0.08) ($0.06) ($0.06) ($0.27)
Adjusted Weighted Average Basic Shares Outstanding		 67.50M 4.74M 4.31M 0.00 68.05M 71.55M 71.55M 71.55M 73.27M 87.46M 100.03M
Adjusted Diluted Earnings per Share		 ($0.35) $0.07 $0.04 $0.00 ($0.10) ($0.09) ($0.11) ($0.08) ($0.06) ($0.06) ($0.27)
Adjusted Weighted Average Diluted Shares Outstanding		 67.50M 4.74M 4.31M 0.00 68.05M 71.55M 71.55M 71.55M 73.27M 87.46M 100.03M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 2.35M 6.65M 2.36M 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -7.95 -1.87 -3.28 -1.87 -4.67 -3.21 -3.77 -1.97 -3.30 -0.91 -18
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -23.01% -1,053.25%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -133.61% -1,609.84%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -30.76 0.00 -114.58 -812.92
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -21.53 0.00 -80.20 -606.39
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -30.76 0.00 -114.58 -812.92
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -21.53 0.00 -80.20 -606.39
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% -13.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% -13.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Citius Oncology (NASDAQ: CTOR) continues to look like a development-stage biotech with meaningful revenue volatility, heavy operating losses, and a reliance on financing to support the business. The latest quarter showed a sharp drop in revenue from the prior quarter, a very large operating loss, and negative operating cash flow. At the same time, the balance sheet still carries a sizeable asset base and more cash than a year ago, helped by equity issuance.

  • Cash and equivalents increased to $2.6 million in Q2 2026 from $7.3 million in Q1 2026, though it still remains modest relative to liabilities and quarterly burn.
  • The company finished Q2 2026 with $29.4 million in current assets and $100.7 million in total assets, giving it a larger asset base than in earlier periods.
  • Quarterly revenue in Q2 2026 was $1.67 million, showing the business can generate top-line sales despite its early-stage profile.
  • Gross profit in Q2 2026 was $1.34 million, indicating revenue still exceeded direct cost of revenue.
  • Q2 2026 operating cash flow improved versus Q1 2026, with operating cash burn narrowing to $(3.8) million from $(7.4) million.
  • The company reported $22.7 million in inventories, which could support future product activity, but also ties up capital.
  • Total common equity stood at $35.3 million in Q2 2026, down from $58.4 million in Q1 2026, reflecting the impact of ongoing losses.
  • Q2 2026 revenue fell sharply to $1.67 million from $3.94 million in Q1 2026, suggesting uneven sales momentum.
  • The company posted a Q2 2026 net loss of $(26.6) million, much wider than the $(5.5) million loss in Q1 2026.
  • Operating expenses in Q2 2026 surged to $30.0 million, driven by $23.6 million of SG&A and $3.5 million of special charges.
  • Q2 2026 operating income was a loss of $(28.6) million, showing the core business is still far from profitability.
  • Cash from operations remained negative in Q2 2026 at $(3.8) million, after multiple prior quarters of cash burn.
  • The balance sheet shows $65.4 million in total liabilities versus $35.3 million in equity, so leverage and financing risk remain important.
  • A large portion of equity is offset by negative retained earnings of $(96.2) million, reflecting accumulated losses over time.
  • The company has relied on share issuance to fund operations, which can dilute existing shareholders.

Bottom line: CTOR’s financials show a company with continuing commercial activity, but also very large losses, inconsistent quarterly revenue, and persistent dependence on outside funding. Investors should view the balance sheet as providing some runway, but not as evidence of a sustainable earnings profile yet.

07/17/26 01:41 PM ETAI Generated. May Contain Errors.

Citius Oncology Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Citius Oncology's financial year ends in September. Their financial year 2025 ended on September 30, 2025.

Citius Oncology's net income appears to be on an upward trend, with a most recent value of -$24.76 million in 2025, falling from $380.81 thousand in 2022. The previous period was -$21.15 million in 2024. Find out what analysts predict for Citius Oncology in the coming months.

Citius Oncology's total operating income in 2025 was -$23.52 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $23.52 million

Over the last 3 years, Citius Oncology's total revenue changed from $0.00 in 2022 to $0.00 in 2025, a change of 0.0%.

Citius Oncology's total liabilities were at $56.08 million at the end of 2025, a 46.7% increase from 2024, and a 40,971.3% increase since 2021.

In the past 4 years, Citius Oncology's cash and equivalents has ranged from $0.00 in 2021 to $3.92 million in 2025, and is currently $3.92 million as of their latest financial filing in 2025.

Over the last 3 years, Citius Oncology's book value per share changed from 0.04 in 2022 to 0.61 in 2025, a change of 1,486.5%.


Related Companies

Financial statements for NASDAQ:CTOR last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
DOJ Admits It In Court—Your Cash Can Be Seized Without Warning
The Department of Justice recently argued in court that cash may not be legally your property - raising concer...
Priority Gold | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel